公开(公告)号：US20240200146A1

公开(公告)日：2024-06-20

申请号：US18516552

申请日：2023-11-21

Applicant: Genentech, Inc.

Inventor： Christiaan Nicolaas Klijn ,  Shiva Malek ,  Ivana Yen

IPC: C12Q1/6886 ,  A61K31/519 ,  A61K31/553 ,  A61K45/06 ,  A61P35/00

CPC classification number: C12Q1/6886 ,  A61K31/519 ,  A61K31/553 ,  A61K45/06 ,  A61P35/00 ,  C12Q2600/106 ,  C12Q2600/156

Abstract: The present invention provides diagnostic and therapeutic methods and compositions for cancer. The invention provides methods of determining whether an individual having a cancer is likely to respond to treatment comprising a pan-RAF dimer inhibitor and a MEK or PI3K inhibitor, methods of predicting responsiveness of an individual having a cancer to treatment comprising a pan-RAF dimer inhibitor and a MEK or PI3K inhibitor, methods of selecting a therapy for an individual having a cancer, and methods of treating an individual having cancer based on the presence of a biomarker of the invention (e.g., a KRAS activating mutation, e.g., a KRAS-G13D mutation, or an NRAS activating mutation).

公开(公告)号：US11859252B2

公开(公告)日：2024-01-02

申请号：US16644902

申请日：2018-09-07

Applicant: Genentech, Inc.

Inventor： Christiaan Nicolaas Klijn ,  Shiva Malek ,  Ivana Yen

IPC: C12Q1/6886 ,  A61P35/00 ,  A61K31/519 ,  A61K31/553 ,  A61K45/06

CPC classification number: C12Q1/6886 ,  A61K31/519 ,  A61K31/553 ,  A61K45/06 ,  A61P35/00 ,  C12Q2600/106 ,  C12Q2600/156

Abstract: The present invention provides diagnostic and therapeutic methods and compositions for cancer. The invention provides methods of determining whether an individual having a cancer is likely to respond to treatment comprising a pan-RAF dimer inhibitor and a MEK or PI3K inhibitor, methods of predicting responsiveness of an individual having a cancer to treatment comprising a pan-RAF dimer inhibitor and a MEK or PI3K inhibitor, methods of selecting a therapy for an individual having a cancer, and methods of treating an individual having cancer based on the presence of a biomarker of the invention (e.g., a KRAS activating mutation, e.g., a KRAS-G13D mutation, or an NRAS activating mutation).